Evotec (UK) Ltd, 114 Milton Park, Abingdon, Oxfordshire OX14 4SA, United Kingdom.
Protein Sci. 2010 Jan;19(1):168-73. doi: 10.1002/pro.294.
The Mapkap kinases 2 and 3 (MK2 and MK3) have been implicated in intracellular signaling pathways leading to the production of the pro-inflammatory cytokine tumor necrosis factor alpha. MK2 has been pursued by the biopharmaceutical industry for many years for the development of a small molecule anti-inflammatory treatment and drug-like inhibitors have been described. The development of some of these compounds, however, has been slowed by the absence of a high-resolution crystal structure of MK2. Herein we present a high-resolution (1.9 A) crystal structure of the highly homologous MK3 in complex with a pharmaceutical lead compound. While all of the canonical features of Ser/Thr kinases in general and MK2 in particular are recapitulated in MK3, the detailed analysis of the binding interaction of the drug-like ligand within the adenine binding pocket allows relevant conclusions to be drawn for the further design of potent and selective drug candidates.
MAPKAP 激酶 2 和 3(MK2 和 MK3)已被牵涉到导致促炎细胞因子肿瘤坏死因子-α产生的细胞内信号通路中。多年来,生物制药行业一直在研究 MK2 以开发小分子抗炎治疗方法,并且已经描述了一些类似药物的抑制剂。然而,由于缺乏 MK2 的高分辨率晶体结构,这些化合物的开发速度有所放缓。在此,我们展示了与一种药物先导化合物复合物的高度同源的 MK3 的高分辨率(1.9Å)晶体结构。虽然一般丝氨酸/苏氨酸激酶和特别是 MK2 的所有典型特征都在 MK3 中重现,但对药物样配体在腺嘌呤结合口袋中的结合相互作用的详细分析允许为进一步设计有效和选择性的候选药物得出相关结论。